KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Short term Debt (2021 - 2023)

Historic Short term Debt for Pacific Biosciences Of California (PACB) over the last 6 years, with Q3 2023 value amounting to $96.2 million.

  • Pacific Biosciences Of California's Short term Debt changed N/A to $96.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $96.2 million, marking a year-over-year change of. This contributed to the annual value of $172.1 million for FY2022, which is 1060236.32% up from last year.
  • Per Pacific Biosciences Of California's latest filing, its Short term Debt stood at $96.2 million for Q3 2023.
  • Pacific Biosciences Of California's Short term Debt's 5-year high stood at $186.3 million during Q2 2023, with a 5-year trough of $1.6 million in Q4 2021.
  • In the last 3 years, Pacific Biosciences Of California's Short term Debt had a median value of $172.1 million in 2022 and averaged $128.1 million.
  • Within the past 5 years, the most significant YoY rise in Pacific Biosciences Of California's Short term Debt was 1060236.32% (2022), while the steepest drop was 1060236.32% (2022).
  • Quarter analysis of 3 years shows Pacific Biosciences Of California's Short term Debt stood at $1.6 million in 2021, then soared by 10602.36% to $172.1 million in 2022, then tumbled by 44.1% to $96.2 million in 2023.
  • Its Short term Debt stands at $96.2 million for Q3 2023, versus $186.3 million for Q2 2023 and $184.4 million for Q1 2023.